U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid
Martin H. Cohen(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Nancy S. Scher, Grant A. Williams(United States Food and Drug Administration), Ramzi Dagher, Donna Griebel(United States Food and Drug Administration), Gerald H. Sokol(United States Food and Drug Administration), Alison Martin(Cleveland Clinic)
Cited by 56
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k